Clin Colon Rectal Surg 2024; 37(01): 018-021
DOI: 10.1055/s-0043-1762559
Review Article

Management of Dysplasia in Inflammatory Bowel Disease

Merrill Rubens
1   Department of General Surgery, Washington University in St. Louis, St. Louis, Missouri
Radhika Smith
2   Section of Colon and Rectal Surgery, Department of General Surgery, Washington University in St. Louis, St. Louis, Missouri
› Institutsangaben
Funding This publication was supported by the Washington University School of Medicine Surgical Oncology Basic Science and Translational Research Training Program grant T32 CA009621, from the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.


Given the chronic nature of mucosal inflammation present in patients with inflammatory bowel disease (IBD), there is a high risk of dysplastic lesions progressing to cancer, in addition to a high risk of synchronous and/or metachronous cancers developing in those diagnosed with dysplasia. Due to this, consensus guidelines recommend regular surveillance. When visible dysplasia is encountered, options include endoscopic or surgical resection depending on characteristics of the lesion. Advancements in endoscopic tools increasingly allow for endoscopic removal when appropriate. Invisible dysplasia discovered on random biopsy should prompt referral to physicians who specialize in IBD. While surgical resection with proctocolectomy significantly decreases the risk of colorectal cancer, the risk must be balanced against the morbidity of surgery and quality-of-life concerns. Management of dysplasia in IBD patients requires complex decision-making that requires balance of patient values and goals of care with cancer-related risk factors.


Artikel online veröffentlicht:
09. April 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Linson EA, Hanauer SB. Epidemiology of colorectal cancer in inflammatory bowel disease - the evolving landscape. Curr Gastroenterol Rep 2021; 23 (09) 16
  • 2 Riddell RH, Goldman H, Ransohoff DF. et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14 (11) 931-968
  • 3 Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138 (02) 746-774 , 774.e1–774.e4, quiz e12–e13
  • 4 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58 (suppl 6): S3-S43
  • 5 Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81 (03) 489-501.e26
  • 6 Kiran RP, Nisar PJ, Goldblum JR. et al. Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection?. Ann Surg 2012; 256 (02) 221-226
  • 7 Maser EA, Sachar DB, Kruse D, Harpaz N, Ullman T, Bauer JJ. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn's colitis. Inflamm Bowel Dis 2013; 19 (09) 1827-1832
  • 8 Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6 (05) 963-968
  • 9 Choi CH, Rutter MD, Askari A. et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol 2015; 110 (07) 1022-1034
  • 10 De Jong ME, Van Tilburg SB, Nissen LHC. et al. Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study. J Crohn's Colitis 2019; 13 (12) 1485-1491
  • 11 Wijnands AM, de Jong ME, Lutgens MWMD, Hoentjen F, Elias SG, Oldenburg B. Dutch Initiative on Crohn and Colitis (ICC). Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis. Gastroenterology 2021; 160 (05) 1584-1598
  • 12 Cremer A, Demetter P, De Vos M. et al; Belgian Inflammatory Bowel Disease Research and Development (BIRD) Group. Risk of development of more-advanced lesions in patients with inflammatory bowel diseases and dysplasia. Clin Gastroenterol Hepatol 2020; 18 (07) 1528-1536.e5
  • 13 Choi CH, Ignjatovic-Wilson A, Askari A. et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol 2015; 110 (10) 1461-1471 , quiz 1472
  • 14 Lauricella S, Fabris S, Sylla P. Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis. Surg Endosc 2023; 37 (01) 48-61
  • 15 Shergill AK, Lightdale JR, Bruining DH. et al; American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81 (05) 1101-21.e1 , 13
  • 16 Soetikno R, Subramanian V, Kaltenbach T. et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology 2013; 144 (07) 1349-1352 , 1352.e1–1352.e6
  • 17 Manta R, Zullo A, Telesca DA. et al. Endoscopic submucosal dissection for visible dysplasia treatment in ulcerative colitis patients: cases series and systematic review of literature. J Crohn's Colitis 2021; 15 (01) 165-168
  • 18 Kinoshita S, Nishizawa T, Yahagi N, Uraoka T. Endoscopic submucosal dissection in patients with ulcerative colitis. Digestion 2019; 99 (01) 27-32
  • 19 Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol 2019; 25 (30) 4148-4157
  • 20 Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology 2021; 161 (03) 1043-1051.e4
  • 21 Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ. et al; Sociedad Española de Medicina de Familia y Comunitaria y Asociación Española de Gastroenterología. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update. Gastroenterol Hepatol 2018; 41 (09) 585-596
  • 22 Annese V, Beaugerie L, Egan L. et al; ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohn's Colitis 2015; 9 (11) 945-965
  • 23 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114 (03) 384-413
  • 24 Baker DM, Folan AM, Lee MJ, Jones GL, Brown SR, Lobo AJ. A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis. Colorectal Dis 2021; 23 (01) 18-33
  • 25 Thompson-Fawcett MW, Richard CS, O'Connor BI, Cohen Z, McLeod RS. Quality of life is excellent after a pelvic pouch for colitis-associated neoplasia. Dis Colon Rectum 2000; 43 (11) 1497-1502
  • 26 Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc 2009; 69 (07) 1299-1310
  • 27 Cleveland NK, DiNardi N, Rubin DT. Role of endoscopic management in ulcerative colitis patients with dysplasia. In: Hyman N, Fleshner P, Strong S. eds. Mastery of IBD Surgery. Switzerland: Springer Nature Switzerland AG; 2019: 255-261